K123753

7 IMDx VanR for Abbott m2000 Supplement IMDx Response to FDA Request for Additional Information

# 510(k) SUMMARY

# Date of Summary:

July 10, 2013

# Product Name

IMDx VanR for Abbott m2000

Sponsor

Intelligent Medical Devices, Inc. 19 Blackstone Street Cambridge, MA 02139

# Correspondent

MDC Associates, LLC   
Fran White, Regulatory Consultant   
180 Cabot Street   
Beverly, MA 01915

# Device Identification

Trade or Proprietary Name:   
Common or Usual Name:   
Product Code:   
Regulation Section:   
Device Class:   
Panel:   
IMDx VanR for Abbott $m 2 0 0 0$   
Vancomycin-resistant enterococci detection assay   
NIJ, 001   
21 CFR 866.1640 Antimicrobial susceptibility test powder   
Class II   
83; Microbiology

# Device Description

The IMDx VanR for Abbott $m 2 0 0 0$ assay is a PCR-based assay that targets regions unique to the vanA and vanB vancomycin resistance genes that may be associated with vancomycin resistant Enterococcus (VRE). Detection of the vanA and vanB genes is measured by the presence of fluorescently-labeled oligonucleotide probes that generate a fluorescent signal when specifically bound to amplified vanA and/or vanB PCR products. Differentiation of vanA from vanB is attained by labeling the oligonucleotide probes with different colored fluorescent dyes. The amplification cycle at which fluorescent signal is detected by the Abbott $m 2 0 0 0 r t$ is inversely proportional to the vanA and vanB DNA target level present in the sample.

The IMDx VanR for Abbott $m 2 0 0 0$ assay includes reagents for the detection of the assay process control, which contains inactivated bacteria, unrelated to enterococci, and is introduced into each specimen during sample preparation. The process control (also acting as an internal control (IC)) is co-extracted with the specimen and co-amplified in the same PCR reaction as the vanÁ and vanB targets. The IC demonstrates that the entire assay process has proceeded within specification.

# Intended Use

The IMDx VanR for Abbott $m 2 0 0 0$ assay is an in vitro diagnostic assay that uses polymerase chain reaction (PCR) amplification for the qualitative detection of nucleic acids encoding the

# 510(k) K123753: IMDx VanR for Abbott m2000 Supplement IMDx Response to FDA Request for Additional Information

vancomycin resistance genes vanA and/or vanB. The assay is performed directly on human perirectal swabs, rectal swabs, or stool specimens from patients at risk for Vancomycin Resistant Enterococcus (VRE) colonization. The IMDx VanR for Abbott $m 2 0 0 0$ assay detects the presence of vanA and vanB genes that can be associated with vancomycin-resistant enterococci. The IMDx VanR for Abbott $m 2 0 0 0$ assay can be used as an aid to identify, prevent and control vancomycin-resistant colonization in healthcare settings. The IMDx VanR for Abbott $m 2 0 0 0$ assay is not intended to diagnose VRE infection nor to guide or monitor treatment of infection. Culture methods are necessary to recover organisms for epidemiology typing and confirmation testing.

# Substantial Equivalency

The IMDx VanR for Abbott $m 2 0 0 0$ assay is substantially equivalent to the BD GeneOhm™M VanR Assay (K102416). Table 1 compares the characteristics of the IMDx VanR for $m 2 0 0 0$ assay (New Device) and the GeneOhm assay (Predicate Device).

Table 1: Substantial Equivalence.   

<table><tr><td rowspan=1 colspan=3>$. $ra}$Similarities</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Predicate DeviceBD GeneOhm VanR Assay(K102416)</td><td rowspan=1 colspan=1>New DeviceIMDx VanR forAbbott m2000</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The BD GeneOhm VanR Assay is aqualitative in vitro test for the rapid detectionof vancomycin-resistant (vanA and vanB)genes directly from perianal or rectal swabs.The BD GeneOhm VanR Assay detects thepresence of the vanA and vanB genes that canbeassociated with vancomycin-resistantenterococci (VRE). The assay is performed onan automated real-time PCR instrument withperianal or rectal swabs from individuals atrisk for VRE colonization. The BD GeneOhmVanR Assay can be used as an aid to identify,prevent and control vancomycin-resistantcolonization in healthcare settings. The BDGeneOhm VanR Assay is not intended todiagnose VRE infections nor to guide ormonitortreatment for VRE infections.Concomitant cultures are necessary to recoverorganisms for epidemiological, susceptibilitytesting  and  for  further confirmatoryidentification.</td><td rowspan=1 colspan=1>The IMDx VanR for Abbott m2000 assayis an in vitro diagnostic assay that usespolymerase   chain  reaction  (PCR)amplification for the qualitative detectionof nucleic acids encoding the vancomycinresistance genes vanA and/or vanB. Theassay is performed directly on human peri-rectal swabs, rectal swabs, or stoolspecimensfrompatients at risk forVancomycin  Resistant   Enterococcus(VRE) colonization. The IMDx VanR forAbbott m2000 assay detects the presenceof vanA andvanBgenes that can beassociated  with  vancomycin-resistantenterococci. The IMDx VanR for Abbottm2000 assay can be used as an aid toidentify, prevent and control vancomycin-resistant colonization in healthcare settings.The IMDx VanR for Abbott m2000 assayis not intended to diagnose VRE infectionnor toguide or monitor treatment ofinfection. Culture methods are necessaryto recover organisms for epidemiologytyping and confirmation testing.</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Perianal or rectal swab specimens</td><td rowspan=1 colspan=1>Rectal and peri-rectal swabsor stool specimens</td></tr><tr><td rowspan=1 colspan=1>Test Principle</td><td rowspan=1 colspan=1>Real-time PCR DNA amplification</td><td rowspan=1 colspan=1>Real-time PCR DNA amplification</td></tr></table>

510(k) K123753: IMDx VanR for Abbott m2000 Supplement IMDx Response to FDA Request for Additional Information   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Predicate DeviceBD GeneOhm VanR Assay(K102416)</td><td rowspan=1 colspan=1>New DeviceIMDx VanR forAbbott m2000</td></tr><tr><td rowspan=1 colspan=1>TargetsDetected</td><td rowspan=1 colspan=1>vanA and vanB</td><td rowspan=1 colspan=1>vanA and vanB</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Positive ControlNegative ControlProcess Control</td><td rowspan=1 colspan=1>Positive ControlNegative ControlProcess Control</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Predicate DeviceBD GeneOhm VanR Assay(K102416)</td><td rowspan=1 colspan=1>New DeviceIMDx VanR for Abbott m2000</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Cepheid SmartCycler System</td><td rowspan=1 colspan=1>Abbott m2000 System</td></tr><tr><td rowspan=1 colspan=1>SamplePreparation</td><td rowspan=1 colspan=1>Manual</td><td rowspan=1 colspan=1>Automated</td></tr></table>

The differences between the IMDx VanR for Abbott $m 2 0 0 0$ assay and the BD GeneOhm VanR Assay do not impact substantial equivalence. Both assays detect vanA and vanB nucleic acids from similar specimen types and have comparable intended uses. The differences noted above do not change the intended use of the IMDx VanR for Abbott $m 2 0 0 0$ and do not raise questions regarding the safety and effectiveness of the device.

# Performance Characteristics Analytical Performance

# Precision (Repeatability/Reproducibility)

Assay precision was measured in four independent studies: within laboratory repeatability, userto-user reproducibility, lot-to-lot reproducibility and instrument-to-instrument reproducibility using a seven-member panel consisting of one vanA and one vanB VRE strain at varying concentrations: Positive (2-3X LoD), Low Positive (LoD) and High Negative $( < 1 X$ LoD). The final panel member was a true negative sample (negative specimen matrix alone).

Table 2 lists $\% \mathrm { { C V } }$ values for precision studies. Table 3 lists $\%$ agreement values for precision studies.

Table 2. Precision (%CV) for vanA/vanB based on CN values.   

<table><tr><td rowspan=2 colspan=1>PrecisionPanel Member</td><td rowspan=2 colspan=1>Reproducibility</td><td rowspan=2 colspan=1>Repeatability</td><td rowspan=2 colspan=1>Lot to Lot</td><td rowspan=1 colspan=2>Instrument to Instrument</td></tr><tr><td rowspan=1 colspan=1>m2000sp</td><td rowspan=1 colspan=1>m2000rt</td></tr><tr><td rowspan=1 colspan=1>vanAPositive</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=1 colspan=1>vanALow Positive</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.7%</td></tr></table>

510(k) K123753: IMDx VanR for Abbott m2000 Supplement IMDx Response to FDA Request for Additional Information   

<table><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>Reproducibility</td><td rowspan=1 colspan=1>Repeatability</td><td rowspan=1 colspan=1>Lot to Lot</td><td rowspan=1 colspan=2>Instrument to Instrument</td></tr><tr><td rowspan=1 colspan=1>vanAHigh Negative</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>2.8%</td></tr><tr><td rowspan=1 colspan=1>vanBPositive</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=1 colspan=1>vanBLow Positive</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=1 colspan=1>vanBHigh Negative</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Table 3. Precision $\%$ Agreement).   

<table><tr><td rowspan=2 colspan=1>PrecisionPanelMember</td><td rowspan=2 colspan=1>ExpectedPositivity</td><td rowspan=2 colspan=1>Reproducibility</td><td rowspan=2 colspan=1>Repeatability</td><td rowspan=2 colspan=1>Lot to.Lot</td><td rowspan=1 colspan=2>Instrument toInstrument</td></tr><tr><td rowspan=1 colspan=1>m2000sp</td><td rowspan=1 colspan=1>m2000rt</td></tr><tr><td rowspan=1 colspan=1>vanAPositive</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>97.2%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>vanALow Positive</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>95.8%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>vanAHighNegative</td><td rowspan=1 colspan=1>20 - 80%</td><td rowspan=1 colspan=1>66.7%</td><td rowspan=1 colspan=1>55.6%</td><td rowspan=1 colspan=1>44.4%</td><td rowspan=1 colspan=1>55.6%</td><td rowspan=1 colspan=1>55.6%</td></tr><tr><td rowspan=1 colspan=1>vanBPositive</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>vanBLow Positive</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>vanBHighNegative</td><td rowspan=1 colspan=1>20 - 80%</td><td rowspan=1 colspan=1>35.6%</td><td rowspan=1 colspan=1>27.8%</td><td rowspan=1 colspan=1>55.6%</td><td rowspan=1 colspan=1>16.7%</td><td rowspan=1 colspan=1>27.8%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0%</td></tr></table>

# Analytical Sensitivity (Limit of Detection)

Limit of Detection (LoD) studies were conducted to determine the lowest concentration of each target analyte that could be detected $\ge 9 5 \%$ of the time. Six strains of vancomycin-resistant Enterococcus, four VanA-type and two VanB-type, were tested. Dilutions of quantified bacterial stocks were tested in replicates of sixty (60). The LoD of the assay was estimated using probit analysis for each target (vanA and vanB). The observed LoD for VRE strains tested is provided in Table 4.

# 510(k) K123753: IMDx VanR for Abbott m2000 Supplement IMDx Response to FDA Request for Additional Information

Table 4. Limit of Detection   

<table><tr><td rowspan=1 colspan=1>Strain</td><td rowspan=1 colspan=1>Genotype</td><td rowspan=1 colspan=1>Limit of Detection (95% CI)</td></tr><tr><td rowspan=1 colspan=1>E. faecium ATCC 51559</td><td rowspan=1 colspan=1>vanA</td><td rowspan=1 colspan=1>1010.7 CFU/swab  (975.1-1047.5)</td></tr><tr><td rowspan=1 colspan=1>E. faecium ATCC700221</td><td rowspan=1 colspan=1>vanA</td><td rowspan=1 colspan=1>4300.6 CFU/swab  (3862.6 - 4788.2)</td></tr><tr><td rowspan=1 colspan=1>E. faecium ATCCBAA-2318</td><td rowspan=1 colspan=1>vanA</td><td rowspan=1 colspan=1>889.0 CFU/swab   (777.1 - 1017.0)</td></tr><tr><td rowspan=1 colspan=1>E. faecium ATCCBAA-2320</td><td rowspan=1 colspan=1>vanA</td><td rowspan=1 colspan=1>2435.4 CFU/swab  (2043.9-2901.7)</td></tr><tr><td rowspan=1 colspan=1>E. faecalis ATCC 51575</td><td rowspan=1 colspan=1>vanB</td><td rowspan=1 colspan=1>810.1 CFU/swab   (571.7-1147.8)</td></tr><tr><td rowspan=1 colspan=1>E. faecalis ATCC 700802</td><td rowspan=1 colspan=1>vanB</td><td rowspan=1 colspan=1>1610.0 CFU/swab  (1569.1 - 1652.0)</td></tr></table>

# Analytical Reactivity

Eighty-eight (88) well-characterized vancomycin-resistant Enterococcus strains and/or clinical isolates (43 VanA-type and 45 VanB-type) were evaluated with the IMDx VanR for Abbott $m 2 0 0 0$ assay.ltras wee deee b the asy.

# Challenge Study

A challenge study was conducted using a panel of 72 well-characterized strains of Enterococcus: 23 vanA strains, 25 vanB strains, 2 strains with both vanA and vanB genes, 1 strain with both vanA and vanC genes, 5 vanC strains, 3 vanD strains, 2 vanE strains, 1 vanG strain, and 10 vancomycin-susceptible strains. All Enterococcus strains harboring vanA or vanB resistance genes were detected. All Enterococcus strains harboring vanC, vanD, vanE, or vanG resistance genes and all vancomycin-sensitive Enterococcus strains were not detected by the IMDx VanR for Abbott $m 2 0 0 0$ assay.

# Cross-Reactivity/Microbial Interference

The IMDx VanR for Abbott $m 2 0 0 0$ assay was evaluated for potential cross-reactivity and/or interference using a panel of 96 organisms that may be present in rectal, peri-rectal and stool samples. Included in the panel were 13 vancomycin-sensitive Enterococcus strains and 10 vancomycin-resistant (non-vanA/vanB) Enterococcus strains. Bacteria were tested at a concentration $\mathsf { \Omega } _ { 1 } \mathsf { f } \geq \mathsf { \Omega } _ { 1 } \mathrm { ~ x ~ } \mathsf { \bar { \Omega } } _ { 1 0 } { } ^ { 6 } \mathrm { ~ C F U / m L }$ , and viruses at a concentration of $\geq 1 \mathrm { ~ x ~ } 1 0 ^ { 5 } \mathrm { ~ T C I D } _ { 5 0 } / \mathrm { m L }$ . None of the organisms tested were found to cross-react or interfere with the IMDx VanR for Abbott $m 2 0 0 0$ assay.

# Vancomycin-Resistant Staphylococcus aureus (VRSA) strains

Twelve (12) VRSA (VanA-type) isolates from the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) were tested with the IMDx VanR for Abbott $m 2 0 0 0$ assay. The vanA gene was detected in all strains. The vanB gene was not detected in any of the strains. Since S. aureus may harbor vanA and vanB vancomycin resistance genes, the IMDx VanR for Abbott $m 2 0 0 0$ assay may produce detected results if S. aureus organisms harboring these genes are present in the clinical specimen.

# 510(k) K123753: IMDx VanR for Abbott m2000 Supplement IMDx Response to FDA Request for Additional Information

# Interfering Substances

The IMDx VanR for Abbott $m 2 0 0 0$ assay was challenged with twenty-three (23) substances that may be present in rectal, peri-rectal or stool specimens. The substances included: anti-fungal/ anti-itch vaginal cream, suppositories, anti-hemorrhoid creams/ointments, antacids, enemas, condoms with spermicidal lubricant, anti-diarrheal medication, laxatives, antibiotics (oral and topical), non-steroidal anti-inflammatory medications, moist towelettes, fecal components (e.g. blood, mucus, fecal lipid), and MRl contrast agent. No assay interference was observed for any of the substances.

# Clinical Performance Characteristics

The performance of the IMDx VanR for Abbott $m 2 0 0 0$ assay was assessed by comparison to enriched culture combined with confirmation of the molecular basis of vancomycin resistance of isolates using an alternate PCR method. Samples were collected from five geographically diverse test sites within the United States. The patient distribution, by age, is shown in Figure . Samples enrolled for this study included a total of 587 peri-rectal swabs. 444 rectal swabs, and 469 stool specimens. Assay performance, by specimen type, is listed in Tables 5-10. Tables 11-12 presents Assay performance by genotype detected.

![](images/7f0bfe86dbbe2ec78d3369e5904476adc21c65a48bf3fad2d0a60ff1d4b1d1de.jpg)  
Figure 1. Patient Population. Subjects ranged in age from ${ < } 1$ to 98 years old.

# 510(k) K123753: IMDx VanR for Abbott m2000 Supplement IMDx Response to FDA Request for Additional Information

Table 5. Peri-rectal Swab Specimens: IMDx vs. Enriched Culture and Alternative PCR.   
Enriched Culture $^ +$ Alternative PCR   
IMDx VanR for Abbott m2000   
Table 6.   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>VanA-typeEnterococcus</td><td rowspan=1 colspan=1>VanB-typeEnterococcus</td><td rowspan=1 colspan=1>VanA-type andVanB-typeEnterococcus</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>vanA</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>52</td></tr><tr><td rowspan=1 colspan=1>vanB</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>vanA and vanB</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>504</td><td rowspan=1 colspan=1>507</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>537</td><td rowspan=1 colspan=1>587</td></tr></table>

# Resulting Truth Table for Peri-rectal Swab Specimens: IMDx vs. Enriched Culture and Alternative PCR.

Enriched Culture $^ +$ Alternative PCR   

<table><tr><td rowspan=4 colspan=1>MDx VanRfor Abbottm2000</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>504</td><td rowspan=1 colspan=1>507</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>537</td><td rowspan=1 colspan=1>587</td></tr></table>

95% CI Sensitivity $9 4 . 0 \%$ $( 8 3 . 8 \% - 9 7 . 9 \% )$ Specificity EMPY $9 3 . 9 \%$ EMPY (91.5% - 95.6%)   
Positive Predictive Value EMP $5 8 . 8 \%$ EMP $( 4 7 . 8 \% - 6 8 . 9 \% )$   
Negative Predictive Value EMPY $9 9 . 4 \%$ $( 9 8 . 3 \% - 9 9 . 8 \% )$ Prevalence EMP $8 . 5 \%$ EMP

# Table 7. Rectal Swab Specimens (Prospective Collection): IMDx vs. Enriched Culture and Alternative PCR.

Enriched Culture $^ +$ Alternative PCR   
IMDx VanR for Abbott $m 2 0 0 0$   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>VanA-typeEnterococcus</td><td rowspan=1 colspan=1>VanB-typeEnterococcus</td><td rowspan=1 colspan=1>VanA-type andVanB-typeEnterococcus</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>vanA</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=1 colspan=1>vanB</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>vanA and vanB</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>309</td><td rowspan=1 colspan=1>311</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>337</td><td rowspan=1 colspan=1>400</td></tr></table>

# 510(k) K123753: IMDx VanR for Abbott m2000 Supplement IMDx Response to FDA Request for Additional Information

Table 8. Resulting Truth Table from Rectal Swab Specimens (Prospective Collection): IMDx vs. Enriched Culture and Alternative PCR.

Enriched Culture $^ { + }$ Alternative PCR   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>89</td></tr><tr><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>309</td><td rowspan=1 colspan=1>311</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>337</td><td rowspan=1 colspan=1>400</td></tr></table>

95% CI Sensitivity $9 6 . 8 \%$ b $( 8 9 . 1 \% - 9 9 . 1 \% )$ EY Specificity $9 1 . 7 \%$ EPY $( 8 8 . 3 \% \cdot 9 4 . 2 \% )$ EPY   
Positive Predictive Value $6 8 . 5 \%$ $( 5 8 . 3 \% - 7 7 . 2 \% )$ EPY   
Negative Predictive Value EMP $9 9 . 4 \%$ EMP $( 9 7 . 7 \% - 9 9 . 8 \% )$ EP Prevalence $1 5 . 8 \%$ EY

# Table 9. Rectal Swab Specimens (Retrospective Collection): IMDx vs. Enriched Culture and Alternative PCR.

Enriched Culture $^ +$ Alternative PCR   
IMDx VanR for Abbott m2000   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>VanA-typeEnterococcus</td><td rowspan=1 colspan=1>VanB-typeEnterococcus</td><td rowspan=1 colspan=1>VanA-type andVanB-typeEnterococcus</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>vanA</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=1 colspan=1>vanB</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0     •</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>vanA and vanB</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>44</td></tr></table>

# Table 10. Resulting Truth Table from Rectal Swab Specimens (Retrospective Collection): IMDx vs. Enriched Culture and Alternative PCR.

Enriched Culture $^ +$ Alternative PCR   

<table><tr><td rowspan=4 colspan=1>MDx VanRfor Abbottm2000</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>44</td></tr><tr><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>44</td></tr></table>

# 510(k) K123753: IMDx VanR for Abbott m2000 Supplement IMDx Response to FDA Request for Additional Information

95% CI Positive Percent Agreement $1 0 0 . 0 \%$ $( 9 1 . 6 \% - 1 0 0 . 0 \% )$ Negative Percent Agreement $0 . 0 \%$ EPY $( 0 . 0 \% - 6 5 . 8 \% )$

Table 11. Stool Specimens: IMDx vs. Enriched Culture and Alternative PCR.   
Enriched Culture $+$ Alternative PCR   
IMDx VanR for Abbott m2000   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>VanA-typeEnterococcus</td><td rowspan=1 colspan=1>VanB-typeEnterococcus</td><td rowspan=1 colspan=1>VanA-type andVanB-typeEnterococcus</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>vanA</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>57</td></tr><tr><td rowspan=1 colspan=1>vanB</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>47</td></tr><tr><td rowspan=1 colspan=1>vanA and vanB</td><td rowspan=1 colspan=1>.9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Not Detected</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>343</td><td rowspan=1 colspan=1>350</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>469</td></tr></table>

\* Considered as a false negative result for the $2 \mathbf { x } 2$ table below

# Table 12. Resulting Truth Table from Stool Specimens: IMDx vs. Enriched Culture and Alternative PCR.

Enriched Culture $^ +$ Alternative PCR   

<table><tr><td rowspan=4 colspan=1>IMDx VanRfor Abbottm2000</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>117</td></tr><tr><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>343</td><td rowspan=1 colspan=1>352</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>469</td></tr></table>

95% CI Sensitivity $8 7 . 0 \%$ $( 7 7 . 0 \% - 9 3 . 0 \% )$ EPY Specificity $8 5 . 8 \%$ $( 8 2 . 0 \% - 8 8 . 8 \% )$ EPY   
Positive Predictive Value EY $5 1 . 3 \%$ $( 4 2 . 3 \% \cdot 6 0 . 2 \% )$ EP   
Negative Predictive Value $9 7 . 4 \%$ $( 9 5 . 2 \% - 9 8 . 6 \% )$ EPY Prevalence $1 4 . 7 \%$ EPY

# Conclusions

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

INTELLIGENT MEDICAL DEVICES, INC.C/O FRAN WHITE  
REGULATORY CONSULTANT  
MDC ASSOCIATES  
180 CABOT STREET  
BEVERLY MA 01915

Re: K123753 Trade/Device Name: IMDx VanR for Abbott $\pmb { m } 2 0 0 0$ Assay Regulation Number: 21 CFR 866.1640 Regulation Name: Antimicrobial susceptibility test powder Regulatory Class: II Product Code: NIJ, OOI Dated: June 13, 2013 Received: June 14, 2013

Dear Ms. White:

We have reviewed your Section ${ \mathfrak { s l } } 0 ( { \mathfrak { k } } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class I (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Small Manufacturers, International and Consumer   
Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http:/www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also. please note the regulation entitled, "Misbranding by refcrence to premarket notification" (21CFR Par 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go t0   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/dcfault.htm for the CDRHl's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internel address http://www.fda.gov/MedicalDevices/ResourccsforYou/Industry/default.htm.

Sincerely yours,

# Uwe Scherf -S for

Sally A. Hojvat, M.Se.. Ph.D. Director, Division of Microbiology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

# Indications for Use

# 510(k) Number:

# K123753

Device Name:

IMDx VanR for Abbott m2000

Indications for Use:

The IMDx VanR for Abbott m2000 assay is an in vitro diagnostic assay that uses polymerase chain reaction (PCR) amplification for the qualitative detection of nucleic acids encoding the vancomycin resistance genes vanA and/or vanB. The assay is performed directly on human perirectal swabs, rectal swabs, or stool specimens from patients at risk for Vancomycin-Resistant Enterococcus (VRE) colonization. The IMDx VanR for Abbott $m 2 0 0 0$ assay detects the presence of vanA and vanB genes that can be associated with vancomycin-resistant enterococci. The IMDx VanR for Abbot $\pmb { m } 2 0 0 0$ assay can be used as an aid to identify, prevent and control vancomycin-resistant colonization in healthcare settings. The IMDx VanR for Abbott $\pmb { m } 2 0 0 0$ EY assay is not intended to diagnose VRE infection nor to guide or monitor treatment of infection. Culture methods are necessary to recover organisms for epidemiology typing and confirmation testing.

Prescription Use X (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

# Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)